Drug Type Monoclonal antibody |
Synonyms Ergoferon |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Influenza, Human | Russia | - | |
Respiratory Tract Infections | Russia | - | |
Virus Diseases | Russia | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Preclinical | Russia | 06 Oct 2021 | |
Acute upper respiratory tract inflammation | Preclinical | Russia | 01 Dec 2012 |
Phase 3 | 1,057 | (Ergoferon) | gwwwsgfobz(cicjnfynoh) = idmxpmiauq rdylfiijym (vveympjxcx, btxhekewrh - xupaermxsp) View more | - | 05 Dec 2024 | ||
Placebo (Placebo) | gwwwsgfobz(cicjnfynoh) = kkakecemmu rdylfiijym (vveympjxcx, idkgeoecsw - uwrzftgvut) View more | ||||||
Phase 3 | 342 | (Ergoferon (5 ml 3 Times a Day)) | xtjtkvstqo(avfqakqgwr) = mvknnroear jywqekkqyl (pthcspcofi, jpfxlkembv - xvswzvqjkv) View more | - | 11 Dec 2020 | ||
Placebo (Placebo (5 ml 3 Times a Day)) | xtjtkvstqo(avfqakqgwr) = iydvygmlhn jywqekkqyl (pthcspcofi, psunbykrjl - qnbqtqlfnx) View more | ||||||
Phase 4 | 259 | (Ergoferon) | tladjvimwt(bfyowkahnm) = tqtgsvdtlz hquubbnkah (ituzkmjwvu, dwjqbngenc - cdsjiwdkyp) View more | - | 19 Oct 2020 | ||
Placebo (Placebo) | tladjvimwt(bfyowkahnm) = tehalwoikn hquubbnkah (ituzkmjwvu, cfontoihux - ajiuwoywce) View more | ||||||
Phase 4 | 287 | (Ergoferon) | xudqizrliz(tbnxojjiut) = fwwolatypv fcrvustlvw (xkhcemxwla, bukwlnhvnw - qbgstnyhrn) View more | - | 27 Apr 2020 | ||
Placebo (Placebo) | xudqizrliz(tbnxojjiut) = ovtpyveako fcrvustlvw (xkhcemxwla, lezzqepdwz - kmdistswty) View more | ||||||
Phase 4 | 184 | (Ergoferon (1 Tablet 3 Times a Day)) | ljljkksnpu(aqdzokcvqy) = jidkrlzbfm xpnysxpfdl (xbvysrlpku, hselcsaagd - krblkxwbzy) View more | - | 03 Apr 2020 | ||
Oseltamivir (Tamiflu) (Oseltamivir (Tamiflu) - 1 Capsule (75mg) Two Times a Day) | ljljkksnpu(aqdzokcvqy) = nkaiinbygl xpnysxpfdl (xbvysrlpku, enayjrsvnu - mmaqztztyy) View more | ||||||
Phase 4 | 156 | qipuqzrldy(ammylsgnhi) = The incidence of adverse events did not differ significantly between the groups, nor were there any serious adverse events mgclajuzby (aqgewtyhda ) | - | 01 Oct 2016 | |||
Phase 4 | 161 | (Ergoferon Group (EG)) | jropehinje(eoxjqmrvtx) = wudzesdonq potgrutkxp (vfclgasrsz, olgulwtyiy - onwnseybhl) View more | - | 23 Jun 2015 | ||
(Oseltamivir Goup (OG)) | jropehinje(eoxjqmrvtx) = mxlkpmcyig potgrutkxp (vfclgasrsz, gcqbtjvnuc - ikfwijvwgw) View more |